Conquering cancer's infamous KRAS mutation

May 14, 2019

LA JOLLA, CALIF. - May 14, 2019 - KRAS is one of the most challenging targets in cancer. Despite its discovery more than 60 years, researchers still struggle to inhibit its mutated form--earning its reputation as "undruggable." Yet, the hunt for an Achilles' heel continues, as cancers driven by KRAS mutations are both common and deadly.

Now, scientists from Sanford Burnham Prebys and PHusis Therapeutics have shown that a compound called PHT-7.3 shrinks KRAS-driven tumors in mice. In contrast to directly targeting mutant KRAS, the potential drug candidate targets the protein's partner in crime: the cellular scaffold to which mutated KRAS attaches. The study was published in Cancer Research.

"Researchers have successfully developed personalized therapies for other mutations known to drive cancer growth, such as EGFR and BRAF. However, KRAS has remained infamously elusive," says Garth Powis, D.Phil, senior author of the paper, director of Sanford Burnham Prebys' NCI-designated Cancer Center and scientific co-founder and adviser to PHusis Therapeutics. "Our study identifies a promising compound that has the potential to become a much-needed treatment for KRAS-driven cancers, an important advance for the millions of people around the world who are fighting this deadly cancer type."

KRAS is a protein that regulates cell growth. If it becomes mutated, it can get stuck in the "always on" conformation, leading to the uncontrolled cellular growth that causes cancer. The mutation occurs in approximately 25 percent of all human cancers, including more than 90 percent of pancreatic cancers, 35 to 45 percent of colorectal cancers and approximately 25 percent of lung cancers. There is currently no effective treatment for KRAS-positive cancers.

"Mutated KRAS is firing all the time--similar to speedily typed Morse code versus a calm, intermittent key tap," explains Powis. "This out-of-control signaling drives tumor growth--and is particularly insidious because it overpowers targeted therapies that may otherwise have been able to treat the cancer."

In the study, the scientists focused on mutant KRAS' accomplice, a protein called Cnksr1 (connector enhancer of kinase suppressor of Ras 1). Mutant KRAS floats to the cellular membrane and attaches to this scaffold to become active. After demonstrating that inhibiting Cnksr1 halts the growth of lung and colon cancer cells, the researchers conducted molecular modeling and structural modifications to identify PHT-7.3. This small molecule probe--the starting point for further drug development--shrank KRAS-driven tumors in a mouse model of non-small-cell lung cancer. Importantly, the compound did not affect the function of healthy KRAS--indicating that potential side effects may be limited.

PHT-7.3 is currently undergoing lead optimization activities and preclinical development by PHusis Therapeutics.
-end-
The co-first authors of the study are Martin Indarte, Ph.D., of PHusis Therapeutics; and Roisin Puentes, Ph.D., of Sanford Burnham Prebys.

Additional authors include Marco Maruggi, Ph.D., Geoffrey Grandjean, Ph.D., Robert Lemos Jr., Fabiana I. A. L. Layng, Ph.D., Ricardo G. Correa, Ph.D., Laurie A. Bankston, Ph.D., and Robert C. Liddington, Ph.D., of Sanford Burnham Prebys; Nathan T. Ihle, Ph.D., formerly of University of Texas MD Anderson Cancer Center and currently of Pfizer; Zamal Ahmed, Ph.D., Shuxing Zang, Ph.D., Lei Du-Cuny, Ph.D., of University of Texas MD Anderson Cancer Center; and Emmanuelle J. Meuillet, Ph.D., Michael Scott and Lynn Kirkpatrick, Ph.D., of PHusis Therapeutics.

The study's DOI is 10.1158/0008-5472.CAN-18-2372.

Research reported in this press release was supported by the U.S. National Institutes of Health (NIH) (CA185054, CA201707 and P30CA030199). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

About Sanford Burnham Prebys Medical Research Institute

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For over 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children's diseases, and is anchored by our NCI-designated cancer center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.

Sanford Burnham Prebys Medical Discovery Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.